[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP4815798B2 - Copper-containing composition for oral administration - Google Patents

Copper-containing composition for oral administration Download PDF

Info

Publication number
JP4815798B2
JP4815798B2 JP2004365506A JP2004365506A JP4815798B2 JP 4815798 B2 JP4815798 B2 JP 4815798B2 JP 2004365506 A JP2004365506 A JP 2004365506A JP 2004365506 A JP2004365506 A JP 2004365506A JP 4815798 B2 JP4815798 B2 JP 4815798B2
Authority
JP
Japan
Prior art keywords
copper
oral administration
acid
solution
purified water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004365506A
Other languages
Japanese (ja)
Other versions
JP2006169178A (en
Inventor
拓人 武井
和夫 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2004365506A priority Critical patent/JP4815798B2/en
Publication of JP2006169178A publication Critical patent/JP2006169178A/en
Application granted granted Critical
Publication of JP4815798B2 publication Critical patent/JP4815798B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Seasonings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Description

本発明は、銅化合物の不快な味を低減し、服用感を良好にした経口投与用組成物に関する。   The present invention relates to a composition for oral administration in which an unpleasant taste of a copper compound is reduced and a feeling of taking is improved.

銅含有経口投与組成物は銅イオンに由来する不快な味のため飲みにくいものであった。この味は、タンニンやミョウバンなどのタンパクと結合する収斂剤を口にしたときの味(収斂味)と共通のものである。これまで、銅化合物の不快な味を改善するため、オレオレジンやアクセント香料を配合する技術が開示されている(特許文献1)。しかしながら、これらでは銅イオンに由来する不快な味を改善する効果は十分でなかった。   The copper-containing composition for oral administration was difficult to drink due to an unpleasant taste derived from copper ions. This taste is the same as the taste when using an astringent that binds to proteins such as tannin and alum (astringent taste). Until now, in order to improve the unpleasant taste of a copper compound, the technique of mix | blending an oleoresin and an accent fragrance | flavor is disclosed (patent document 1). However, these are not sufficient in improving the unpleasant taste derived from copper ions.

特開平01−153622号公報Japanese Patent Laid-Open No. 01-153622

本発明は、銅イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない銅含有経口投与用組成物を提供することである。   An object of the present invention is to provide a copper-containing composition for oral administration that reduces the astringent taste derived from copper ions, is easy to drink, and does not leave an unpleasant aftertaste.

本発明者らは、上記課題を解決するために鋭意検討を重ねた結果、銅化合物を含有する経口投与用組成物において、コラーゲンペプチド、植物性ペプチドを配合すると銅イオンによるタンパクの凝集(収斂性)が低減し、収斂味が改善されることを見出し、本発明を完成するに至った。すなわち、本発明は、銅化合物にペプチドを配合した経口投与用組成物である。   As a result of intensive studies in order to solve the above problems, the present inventors have found that when a collagen peptide and a vegetable peptide are blended in a composition for oral administration containing a copper compound, protein aggregation (convergence) is caused by copper ions. ) Is reduced and the astringency is improved, and the present invention has been completed. That is, this invention is a composition for oral administration which mix | blended the peptide with the copper compound.

本発明により、銅イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない銅含有経口投与用組成物を提供することができた。   According to the present invention, it is possible to provide a copper-containing composition for oral administration that reduces the astringent taste derived from copper ions, is easy to drink, and does not leave an unpleasant aftertaste.

本発明における銅化合物とは、銅を含む塩であり、アニオンが無毒性であれば有機イオンまたは無機イオンのどちらでもかまわず、有機イオンとしては例えば、グルコン酸、クエン酸、酒石酸等の有機酸イオンを、また無機イオンとしては例えば、硫酸、塩酸、硝酸、リン酸、炭酸等の無機イオンを挙げることができる。好ましい銅化合物としてはグルコン酸銅、硫酸銅、クエン酸銅、塩化銅、硝酸銅およびリン酸銅等が挙げられる。これらは、単独で配合してもよく、2種以上を組み合わせて配合してもよい。   The copper compound in the present invention is a salt containing copper, and if the anion is non-toxic, either an organic ion or an inorganic ion may be used. Examples of the organic ion include organic acids such as gluconic acid, citric acid, and tartaric acid. Examples of the ions and inorganic ions include inorganic ions such as sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, and carbonic acid. Preferred copper compounds include copper gluconate, copper sulfate, copper citrate, copper chloride, copper nitrate and copper phosphate. These may be blended singly or in combination of two or more.

銅化合物の配合量はその使用目的により異なるが、栄養摂取量の面からは、銅イオンに換算して、1日当たり0.1〜10mgが好ましい。なお、1日に100mlの飲料として摂取する場合には、その銅イオン濃度は0.0001〜0.01W/V%である。   The compounding amount of the copper compound varies depending on the purpose of use, but in terms of nutrient intake, 0.1 to 10 mg per day is preferable in terms of copper ions. In addition, when ingesting as a 100 ml drink a day, the copper ion concentration is 0.0001 to 0.01 W / V%.

本発明におけるペプチドとは、タンパク質を酵素あるいは酸で分解させ、タンパク質の機能を向上あるいは新機能を付加させたもので、基質となるタンパク質の種類、酵素の選択、分解、精製方法などにより様々な機能のものがある。このようなタンパク質分解物の中でも特に畜肉又は魚肉由来のコラーゲンペプチド、とうもろこし由来の植物性ペプチドが好ましい。   The peptide in the present invention is a protein that is decomposed with an enzyme or an acid to improve the function of the protein or add a new function. There are functional ones. Among such protein degradation products, collagen peptides derived from livestock meat or fish meat, and plant peptides derived from corn are particularly preferred.

本発明の経口投与用組成物において、銅イオンとペプチドの配合比は、銅イオン1重量部に対して通常0.1重量部以上であり、好ましくは0.5〜30000重量部であり、より好ましくは2.5〜4000重量部である。   In the composition for oral administration of the present invention, the compounding ratio of copper ions and peptides is usually 0.1 parts by weight or more, preferably 0.5 to 30000 parts by weight, based on 1 part by weight of copper ions. Preferably it is 2.5-4000 weight part.

本発明の銅含有経口投与用組成物を内服液剤とする場合には、防腐性および風味等を考慮してそのpHを2.5〜7.0、好ましくは3.0〜5.5とする。この内服液剤のpHは、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸、コハク酸などの有機酸およびその塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を添加して調整することができる。   When the copper-containing composition for oral administration of the present invention is used as an internal solution, the pH is adjusted to 2.5 to 7.0, preferably 3.0 to 5.5 in consideration of antiseptic properties and flavor. . For example, citric acid, malic acid, fumaric acid, tartaric acid, lactic acid, succinic acid, and other organic acids and salts thereof, phosphoric acid, hydrochloric acid, and other inorganic acids, and inorganic bases such as sodium hydroxide are added. Can be adjusted.

本発明の銅含有経口投与用組成物には、ビタミン類、ミネラル類、アミノ酸類、生薬、生薬抽出物、カフェイン、ローヤルゼリーなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤および甘味料等の添加物を本発明の効果を損なわない範囲で適宜に配合できる。   In the copper-containing composition for oral administration of the present invention, vitamins, minerals, amino acids, herbal medicines, herbal extracts, caffeine, royal jelly and the like can be appropriately blended within a range not impairing the effects of the present invention. Moreover, additives such as an antioxidant, a colorant, a fragrance, a corrigent, a surfactant, a solubilizing agent, a preservative, and a sweetener can be appropriately blended as necessary so long as the effects of the present invention are not impaired.

本発明の銅含有経口投与用組成物を調製する方法は特に限定されるものではない。内服液剤とする場合には、通常、各成分を適量の精製水で溶解した後、pHを調整し、残りの精製水を加えて容量調整し、必要に応じて濾過、滅菌処理することにより目的の銅含有経口投与用組成物が得られる。   The method for preparing the copper-containing composition for oral administration of the present invention is not particularly limited. When using it as an internal solution, the purpose is usually to dissolve each component with an appropriate amount of purified water, adjust the pH, adjust the volume by adding the remaining purified water, and filter and sterilize as necessary. A copper-containing composition for oral administration is obtained.

以下に実施例及び試験例を挙げ、本発明をより詳しく説明する。   Hereinafter, the present invention will be described in more detail with reference to examples and test examples.

実施例1
グルコン酸銅 0.004g
グルコン酸亜鉛 0.02g
コーンペプチド 1.00g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
アミノエチルスルホン酸 2.00g
キシリトール 4.00g
トレハロース 5.00g
エリスリトール 5.00g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 1
Copper gluconate 0.004g
Zinc gluconate 0.02g
Corn peptide 1.00g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 2.00g
Xylitol 4.00g
Trehalose 5.00g
Erythritol 5.00g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例2
グルコン酸銅 0.007g
グルコン酸亜鉛 0.05g
コラーゲンペプチド 1.00g
グルコン酸カルシウム 0.80g
硝酸チアミン 0.01g
リボフラビン 0.01g
塩酸ピリドキシン 0.10g
アスコルビン酸 1.00g
アミノエチルスルホン酸 1.00g
ソルビトール 4.00g
トレハロース 5.00g
キシリトール 4.00g
ステビア抽出物 0.03g
アセスルファムカリウム 0.03g
リンゴ酸 0.10g
クエン酸 0.40g
クエン酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
アップルフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 2
Copper gluconate 0.007g
Zinc gluconate 0.05g
Collagen peptide 1.00g
Calcium gluconate 0.80 g
0.01 g of thiamine nitrate
Riboflavin 0.01g
0.10 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 1.00g
Sorbitol 4.00g
Trehalose 5.00g
Xylitol 4.00g
Stevia extract 0.03g
Acesulfame potassium 0.03g
Malic acid 0.10g
Citric acid 0.40g
Sodium citrate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Apple flavor 0.10g
After dissolving the above components in purified water, the pH was adjusted to 4.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例3
グルコン酸銅 0.03g
グルコン酸亜鉛 0.08g
コーンペプチド 0.50g
リボフラビン 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
シアノコバラミン 120μg
パンテノール 0.01g
ニコチン酸アミド 0.05g
アミノエチルスルホン酸 1.00g
ソルビトール 5.00g
トレハロース 2.00g
マルチトール 2.00g
クエン酸 0.40g
リンゴ酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 3
0.03 g of copper gluconate
Zinc gluconate 0.08g
Corn peptide 0.50g
Riboflavin 0.01g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Cyanocobalamin 120μg
Panthenol 0.01g
Nicotinamide 0.05g
Aminoethylsulfonic acid 1.00g
Sorbitol 5.00g
Trehalose 2.00g
Maltitol 2.00g
Citric acid 0.40g
Sodium malate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 4.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例4
グルコン酸銅 0.007g
グルコン酸亜鉛 0.05g
コラーゲンペプチド 0.30g
グルコン酸カルシウム 0.80g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
ニコチン酸アミド 0.10g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ブドウ糖 5.00g
難消化性デキストリン 4.00g
エリスリトール 5.00g
キシリトール 2.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
スクラロース 0.05g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 4
Copper gluconate 0.007g
Zinc gluconate 0.05g
Collagen peptide 0.30g
Calcium gluconate 0.80 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Nicotinamide 0.10g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Glucose 5.00g
Indigestible dextrin 4.00 g
Erythritol 5.00g
Xylitol 2.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Sucralose 0.05g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例5
グルコン酸銅 0.03g
グルコン酸亜鉛 0.08g
コラーゲンペプチド 0.30g
グルコン酸カルシウム 0.40g
乳酸カルシウム 0.50g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.02g
塩酸ピリドキシン 0.03g
ニコチン酸アミド 0.05g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ローヤルゼリー 0.60g
ブドウ糖 5.00g
ソルビトール 5.00g
キシリトール 5.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
クエン酸 0.80g
クエン酸ナトリウム 0.10g
リン酸 0.30g
塩酸 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 5
0.03 g of copper gluconate
Zinc gluconate 0.08g
Collagen peptide 0.30g
Calcium gluconate 0.40g
Calcium lactate 0.50g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.02g
0.03 g of pyridoxine hydrochloride
Nicotinamide 0.05g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Royal jelly 0.60g
Glucose 5.00g
Sorbitol 5.00g
Xylitol 5.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Citric acid 0.80 g
Sodium citrate 0.10g
Phosphoric acid 0.30 g
Hydrochloric acid appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

試験例
Hagermanらは、溶液中のタンパク(ウシ血清アルブミン:BSA)がタンニンにより凝集し、その沈澱量はタンニンの量に比例することを報告した(J.Agric.Food.Chem.,1978,Vol.26,809-812)。本発明者らは、銅イオン溶液にBSA溶液を加えると、この溶液が懸濁し、光の透過量が減少すること、この透過量の減少が、銅イオンの濃度に相関することを見出した。
Test example
Hagerman et al. Reported that protein (bovine serum albumin: BSA) in solution was aggregated by tannin, and the amount of precipitation was proportional to the amount of tannin ( J. Agric . Food . Chem ., 1978, Vol. 26 , 809) . -812). The present inventors have found that when a BSA solution is added to a copper ion solution, the solution is suspended, the amount of light transmission decreases, and the decrease in the amount of transmission correlates with the concentration of copper ions.

試験方法
(1)BSA溶液の調製:BSA(Sigma Chemical Co.;fraction V,fatty acid free)6gを適量の精製水に溶解し、クエン酸100mgを加え、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。
Test method (1) Preparation of BSA solution: 6 g of BSA (Sigma Chemical Co .; fraction V, fatty acid free) is dissolved in an appropriate amount of purified water, 100 mg of citric acid is added, and the pH is adjusted with NaOH solution (1 mol / L). Adjusted to 4.8 and made up to 100 mL with purified water.

(2)希釈液の調製:クエン酸100mgを適量の水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。   (2) Preparation of diluting solution: 100 mg of citric acid was dissolved in an appropriate amount of water, pH was adjusted to 4.8 with NaOH solution (1 mol / L), and purified water was adjusted to 100 mL.

(3)銅イオン溶液の調製:グルコン酸銅0.02g、0.11g及び0.18gにクエン酸0.10gを加えた。それぞれを適量の精製水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。   (3) Preparation of copper ion solution: 0.10 g of citric acid was added to 0.02 g, 0.11 g and 0.18 g of copper gluconate. Each was dissolved in an appropriate amount of purified water, adjusted to pH 4.8 with NaOH solution (1 mol / L), and made up to 100 mL with purified water.

(4)タンパク−銅イオン相互作用(収斂性)の評価
各銅イオン溶液2mLにBSA溶液6mLを加え、希釈液でそれぞれ全量を10mLとした。これを40℃で30分間振とうした。石英セル(L=1cm)を使用し、分光光度計(日立製作所製:U−3300)により、各透明溶液では吸収されない波長である500nmにおける吸光度を測定した。この結果(図1)は、銅イオン濃度と吸光度が相関することを示す。
(4) Evaluation of protein-copper ion interaction (convergence) 6 mL of BSA solution was added to 2 mL of each copper ion solution, and the total volume was adjusted to 10 mL with a diluted solution. This was shaken at 40 ° C. for 30 minutes. Using a quartz cell (L = 1 cm), the absorbance at 500 nm, which is a wavelength that is not absorbed by each transparent solution, was measured with a spectrophotometer (manufactured by Hitachi, Ltd .: U-3300). This result (FIG. 1) shows that the copper ion concentration and the absorbance are correlated.

次に、各種濃度の銅イオン溶液の収斂味を官能評価したときの結果が、当該銅イオン溶液にBSA溶液を加えたときの吸光度と相関していることを確認した。官能評価は、収斂味が強く許容できない場合をB、許容することができる範囲をその収斂味の強さに応じてA4〜A1とし、収斂味を全く感じない場合をAとして行った。   Next, it was confirmed that the results of sensory evaluation of the astringent taste of various concentrations of the copper ion solution correlated with the absorbance when the BSA solution was added to the copper ion solution. The sensory evaluation was performed as B when the astringent taste was strongly unacceptable, A4 to A1 according to the strength of the astringent taste, and A when the astringent taste was not felt at all.

結果を図2に示した。吸光度が約0.3以下であれば、収斂味が充分抑えられていると感じることができた。このことから、ある物質を添加した銅イオン溶液をBSA溶液に混合したときの吸光度が無添加の場合と比較して減少したならば、その物質の添加により、タンパク−銅イオン相互作用による凝集(収斂性)が減少したこと、すなわち収斂味が減少したことを意味することになる。   The results are shown in FIG. When the absorbance was about 0.3 or less, it was felt that the astringent taste was sufficiently suppressed. From this, if the absorbance when a copper ion solution added with a certain substance is mixed with a BSA solution is decreased as compared with the case where no addition is made, the addition of that substance causes aggregation due to protein-copper ion interaction ( This means that the (convergence) has decreased, that is, the astringency has decreased.

(5)検体のタンパク凝集性
上記(1)〜(4)に記載した方法により、表1に示す処方のタンパク凝集性を評価した。結果を併せて表1に示した。
(5) Protein aggregation properties of specimens Protein aggregation properties of the formulations shown in Table 1 were evaluated by the methods described in (1) to (4) above. The results are also shown in Table 1.

Figure 0004815798
Figure 0004815798

表1から、適当な量のコーンペプチド、コラーゲンペプチドを配合した検体1および検体2の吸光度は、対応する検体3より小さいことが分かる。この結果から、コーンペプチド、コラーゲンペプチドの配合により、銅イオンに由来する収斂味を低減できることが明らかとなった。   From Table 1, it can be seen that the absorbance of Sample 1 and Sample 2 containing appropriate amounts of corn peptide and collagen peptide is smaller than the corresponding Sample 3. From this result, it became clear that the astringent taste derived from copper ions can be reduced by blending corn peptide and collagen peptide.

タンパク凝集と銅イオン濃度の相関性を示す。The correlation between protein aggregation and copper ion concentration is shown. 銅イオン溶液にBSA溶液を加えたときに生じる懸濁(タンパク凝集)と銅イオン溶液を官能評価した結果の相関性を示す。The correlation between the suspension (protein aggregation) generated when a BSA solution is added to a copper ion solution and the result of sensory evaluation of the copper ion solution is shown.

本発明の銅含有経口投与用組成物は、例えば、シロップ剤、ドリンク剤などの医薬品や医薬部外品を含む各種製剤及び栄養機能食品などの各種飲料に適用できる。
The copper-containing composition for oral administration of the present invention can be applied to, for example, various preparations including pharmaceuticals such as syrups and drinks and quasi drugs and various beverages such as nutritional functional foods.

Claims (3)

グルコン酸銅、硫酸銅、クエン酸銅、塩化銅、硝酸銅およびリン酸銅からなる群から選ばれる1種又は2種以上の銅化合物と、コラーゲンペプチドおよびコーンペプチドから選ばれる1種又は2種のペプチドを精製水で溶解した後、pHを調整し、残りの精製水を加えて調製した内服液剤であることを特徴とする経口投与用組成物。 One or two or more copper compounds selected from the group consisting of copper gluconate, copper sulfate, copper citrate, copper chloride, copper nitrate and copper phosphate, and one or two selected from collagen peptides and corn peptides A composition for oral administration, wherein the composition is an internal preparation prepared by dissolving pH of the peptide in purified water, adjusting the pH, and adding the remaining purified water . 銅化合物がグルコン酸銅である請求項1に記載の経口投与用組成物。The composition for oral administration according to claim 1, wherein the copper compound is copper gluconate. pHが2.5〜7.0の内服液剤である請求項1又は2のいずれかに記載の経口投与用組成物。 The composition for oral administration according to any one of claims 1 and 2 , which is an internal solution having a pH of 2.5 to 7.0.
JP2004365506A 2004-12-17 2004-12-17 Copper-containing composition for oral administration Expired - Fee Related JP4815798B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004365506A JP4815798B2 (en) 2004-12-17 2004-12-17 Copper-containing composition for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004365506A JP4815798B2 (en) 2004-12-17 2004-12-17 Copper-containing composition for oral administration

Publications (2)

Publication Number Publication Date
JP2006169178A JP2006169178A (en) 2006-06-29
JP4815798B2 true JP4815798B2 (en) 2011-11-16

Family

ID=36670310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004365506A Expired - Fee Related JP4815798B2 (en) 2004-12-17 2004-12-17 Copper-containing composition for oral administration

Country Status (1)

Country Link
JP (1) JP4815798B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073821B1 (en) * 2006-09-28 2012-10-24 Bayer Consumer Care AG Mixture of iron and copper salts masking metallic taste
JP7533917B2 (en) * 2019-03-11 2024-08-14 森永乳業株式会社 Fruit juice flavored beverage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS602163A (en) * 1983-06-17 1985-01-08 Snow Brand Milk Prod Co Ltd Copper-enriching agent bonded with peptide and its preparation
JP3110299B2 (en) * 1994-10-27 2000-11-20 武田薬品工業株式会社 Molded product and method for producing the same
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
JP4147404B2 (en) * 2002-09-27 2008-09-10 国立大学法人信州大学 Plasma volume increase promoter
JP4715078B2 (en) * 2003-04-16 2011-07-06 大正製薬株式会社 Liquid composition for internal use containing iron compounds
JP5162812B2 (en) * 2004-07-08 2013-03-13 大正製薬株式会社 Zinc-containing composition for oral administration

Also Published As

Publication number Publication date
JP2006169178A (en) 2006-06-29

Similar Documents

Publication Publication Date Title
JP4337308B2 (en) Liquid composition
JP5098198B2 (en) Copper compound composition
JP5044957B2 (en) Copper compound composition
JP5167594B2 (en) Composition for internal use liquid containing copper compound
JP5162812B2 (en) Zinc-containing composition for oral administration
JP4622006B2 (en) Iron compound-containing oral solution composition
JP4929628B2 (en) Zinc-containing oral solution
JP5586816B2 (en) Composition containing zinc compound
JP4815798B2 (en) Copper-containing composition for oral administration
JP5398100B2 (en) Oral liquid composition containing iron compound
JP5181486B2 (en) Oral composition containing zinc compound
JP4940492B2 (en) Iron compound combination oral solution
JP5011776B2 (en) Copper compound composition
JP4715078B2 (en) Liquid composition for internal use containing iron compounds
JP5546089B2 (en) Composition containing zinc compound
JP4403595B2 (en) Iron compound-containing oral solution composition
JP2007246509A (en) Oral composition compounded with copper compound
JP4929629B2 (en) Zinc-containing composition for oral administration
AU2018313492B2 (en) Beverage
JP2004315441A (en) Liquid composition for internal use containing iron compound
JP4929589B2 (en) Copper-containing oral administration composition
JP2005255653A (en) Internal liquid medicine formulated with iron compound
JP4645842B2 (en) Royal jelly-containing beverage composition
JP4645841B2 (en) Royal jelly-containing beverage composition
JP2001316246A (en) Iron compound-formulated oral liquid preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071023

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090605

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110329

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110802

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110815

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4815798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees